HWM
SUPN icon

Hemington Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Hemington Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$0 Buy
9
+6
+200% +$242 ﹤0.01% 1714
2025
Q2 		$0 Sell
3
-18
-86% -$577 ﹤0.01% 1702
2025
Q1 		$0 Hold
21
– – ﹤0.01% 1739
2024
Q4 		$0 Hold
21
– – ﹤0.01% 1771
2024
Q3 		$0 Buy
+21
New +$655 ﹤0.01% 1729

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hemington Wealth Management's SUPN Position: Q3 2025 in Review

Hemington Wealth Management increased its Supernus Pharmaceuticals (SUPN) stake by 200% in Q3 2025, buying an estimated $242 and bringing the position to 9 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1714.

Hemington Wealth Management first reported a position in SUPN in Q3 2024 and has held it in 5 quarters since. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Hemington Wealth Management held 9 shares of Supernus Pharmaceuticals worth $0 as of Q3 2025.
  • Hemington Wealth Management bought 6 Supernus Pharmaceuticals shares in Q3 2025, an estimated $242.
  • Supernus Pharmaceuticals made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #1714 holding.
  • Hemington Wealth Management first reported a position in Supernus Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.